Pharma China
Access to the biggest consumer market.
Pharma China Consulting was founded in 2017 in Germany, is a professional insider for license in/out business for China, USA, EU and all over the world with 150 years common experience.
As a Pharma/Biotech consulting company based in Munich Germany we are serving our clients in China, USA, EU to build trust and work together for a long term win-win.
Main Sector: Professional Services and Consulting
Subsector(s): Business development, Deal arrangment, Event organization, Market Research
Primary therapeutic area(s): Cardiovascular, Congenital malformations, deformations and chromosomal abnormalities, Digestive system, Diseases of the blood and blood-forming organs; immune disorders, Diseases of the ear, Diseases of the eye, Diseases of the nervous system, Endocrine, nutritional and metabolic diseases, External causes of morbidity and mortality, Mental and behavioural disorders
Partnering strategy / collaborations
We solve problems for our clients. Our strengths are communications across cultures and deep understanding of the need of our partners.
Client portfolio
Reneo Pharma (USA), Fidia (Italy), Neuraxpharma (Spain), Welding (Germany), Winhealth (Hong Kong), China Resource(China), Hemony (China), Hisun (China), Hasten Pharma (China), Auzone Biotech, Farmamondo (Switzerland), APR(Switzerland) ......
Consulting for Chinese Market
Ms. Hong Xie
- Graduated from China Pharmaceutical University in 1990 with bachelor of science degree.
- Worked for Chengdu pharmaceitical injection factory
- Worked for Bristol-Meyers Squibb in China as Marketing.
- Know running system of hospital, license in/out, pharmacy, pharma wholesaler, research-institute, internet sales, Im&Export ,logistic process.
- Network in whole pharmaceutical business area,including China Food and Drug Administration
- MBA International Marketing title from Germany (FH Reutlingen，Ranking Nr.1 in 2000)
- Consulting experience for China, USA, European pharma companies.
BRIDGE China and World
Source: www.exportinitiative-gesundheitswirtschaft.de
In 2016 China became the second biggest Pharma Market after the USA with a market share of 6%. In 2020 the estimated market volume will reach 109.5 billion USD, with the market share increasing from 5% in 2014 to 7.5% in 2020.
The volume and market share of China Pharma Market in whole world (Unit: Billion Dollar)
source: www.chyxx.com
Greenbridge between China and World
in Pharmaceutical Business Area
Ms. Hong Xie
Ahornring 42 82024 Taufkirchen
Call us:
0049-1772004168
E-mail:
hong.xie@pharma-china.de
